Feedback / Questions
opugotamig olatansine (IMGN-151) - AbbVie
IMGN151: Protection of composition-of-matter patent until 2040
(Immunogen)
-
Nov 6, 2024 -
Corporate Presentation
Patent
•
Oncology
https://investor.immunogen.com/static-files/590a2ec5-4d6f-44fc-98fc-64d1512e8112
Nov 6, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious